Displaying 41–50 of 285 research results
Jan 18, 2022
Foundation Seeks My Retina Tracker Registry Members with X-Linked Retinitis Pigmentosa for Research Survey
Survey results will inform therapy developers and the agenda for a Patient-Focused Drug Development meeting with Food and Drug Administration representatives.
Jan 7, 2022
Foundation’s RD Fund Invests in SalioGen Therapeutics, Developer of Novel Gene Coding Technology for Treating Inherited Retinal Diseases
The company is currently developing programs for Stargardt disease (ABCA4), Usher syndrome, RP25 (EYS), and RP1.
Dec 17, 2021
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
The Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
Dec 13, 2021
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
The clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
Oct 27, 2021
Geographic Atrophy: The Advanced Form of Dry AMD
Geographic atrophy causes significant central vision loss and remains an unmet medical need.
Oct 25, 2021
FDA Approves Genentech’s Susvimo for Treating Wet AMD
The approach significantly reduces the need for regular ocular injections.
Oct 18, 2021
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
The emerging gene therapy is being designed to more safely reach the fovea
Oct 8, 2021
Foundation Hosts Workshop on USH1B Research and Therapy Development
Emerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
Sep 30, 2021
Vision Improvements Reported for Two LCA 10 Patients in Phase 1/2 Clinical Trial for Editas’ CRISPR/Cas9 Treatment
The emerging treatment targets a specific mutation (c.2991+1655A>G in Intron 26) of the gene CEP290 which causes Leber congenital amaurosis 10 (LCA 10)
Sep 28, 2021
RD Fund Launches Opus Genetics to Advance Gene Therapies for Inherited Retinal Diseases
First two programs are for Leber congenital amaurosis: LCA5-lebercillin and LCA13-RDH12